Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials.
Fiche publication
Date publication
mai 2012
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr WESTEEL Virginie, Dr MOUILLET Guillaume
Tous les auteurs :
Mouillet G, Monnet E, Milleron B, Puyraveau M, Quoix E, David P, Ducoloné A, Molinier O, Zalcman G, Depierre A, Westeel V,
Lien Pubmed
Résumé
Our study aimed to evaluate whether pathologic complete response (pCR) in early-stage non-small-cell lung cancer (NSCLC) after neoadjuvant chemotherapy resulted in improved outcome, and to determine predictive factors for pCR.
Mots clés
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Carcinoma, Non-Small-Cell Lung, drug therapy, Carcinoma, Squamous Cell, drug therapy, Chemotherapy, Adjuvant, Cisplatin, administration & dosage, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Female, Humans, Ifosfamide, administration & dosage, Lung Neoplasms, drug therapy, Male, Middle Aged, Mitomycin, administration & dosage, Neoadjuvant Therapy, Neoplasm Staging, Prognosis, Remission Induction, Survival Rate
Référence
J Thorac Oncol. 2012 May;7(5):841-9